Achieve Life Sciences Secures $354 Million Funding for Cytisinicline Development as FDA Review Continues
Key Insights
Achieve Life Sciences announced a $354 million private placement led by major healthcare investors to advance cytisinicline development for nicotine dependence (search) treatment.
The funding includes $180 million upfront with an additional $174 million available through warrants exercisable within 20 days of FDA approval for smoking cessation.
Proceeds will fund a Phase 3 clinical trial for cytisinicline in e-cigarette cessation and commercialization efforts, with FDA review ongoing under a June 2026 PDUFA date.
Achieve Life Sciences has secured up to $354 million in private placement funding to advance the development and commercialization of cytisinicline, a plant-based treatment for nicotine dependence (search), as the company awaits FDA approval for smoking cessation. The transaction, led by prominent healthcare investors including Frazier Life Sciences (search), TPG Life Sciences Innovations (search), and venBio Partners (search), provides $180 million in immediate funding with an additional $174 million available through milestone-driven warrants.
Major Investment Signals Confidence in Nicotine Cessation Market
The private placement attracted participation from both new and existing investors, including Coastlands Capital, Dialectic Capital, Janus Henderson Investors, LifeSci Venture Partners, Logos Capital, Propel Bio Partners, Spruce Street Capital, Venrock Healthcare Capital Partners, Vivo Capital, and Wellington Management. Morgan Stanley (search) served as the sole placement agent for the transaction, which is expected to close on April 17, 2026.
The warrant structure ties additional funding directly to regulatory success, with accompanying warrants exercisable at $3.51 per share becoming available within 20 days of FDA approval for cytisinicline in smoking cessation. This milestone-based approach reflects investor confidence in the drug's regulatory prospects while providing substantial capital for expansion into additional indications.
Leadership Transition and Strategic Focus
In connection with the funding, Achieve Life Sciences appointed Dr. Andrew D. Goldberg as Chief Executive Officer and board member, effective following the transaction's closing. Dr. Goldberg, a dual board-certified physician, brings expertise in healthcare investment, commercial strategy, and clinical medicine. Current President and CEO Richard Stewart will continue serving on the board of directors.
The company plans to use proceeds to fund a Phase 3 clinical trial for cytisinicline in e-cigarette cessation, advance commercialization efforts, and support general corporate purposes. This strategic focus addresses a significant unmet medical need, as there are currently no FDA-approved treatments specifically indicated for nicotine e-cigarette cessation.
Regulatory Timeline and Market Opportunity
Cytisinicline's New Drug Application, submitted to the FDA in June 2025, has been accepted for review with a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026. The application for smoking cessation in adults is based on two successfully completed Phase 3 studies and an open-label safety study. Additionally, the company has completed a Phase 2 study in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication.
The market opportunity is substantial, with approximately 25 million adults in the United States smoking combustible cigarettes and nearly 18 million using e-cigarettes. Tobacco use (search) remains the leading cause of preventable death, responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually. Among youth, approximately 1.6 million middle and high school students reported using e-cigarettes in 2024.
Mechanism and Breakthrough Designation
Cytisinicline is a plant-based alkaloid with high binding affinity to the nicotinic acetylcholine receptor (search). The drug is believed to aid in treating nicotine addiction (search) by interacting with nicotine receptors in the brain, reducing the severity of nicotine craving symptoms, and diminishing the reward and satisfaction associated with nicotine products.
The FDA has awarded cytisinicline the Commissioner's National Priority Voucher for e-cigarette or vaping cessation and granted Breakthrough Therapy designation, recognizing the critical need for effective treatments in this therapeutic area. These designations underscore the regulatory agency's recognition of cytisinicline's potential to address significant unmet medical needs in nicotine dependence (search) treatment.
The substantial funding positions Achieve Life Sciences to advance cytisinicline through regulatory approval and into commercial launch, potentially establishing the first FDA-approved treatment specifically for e-cigarette cessation while expanding treatment options for traditional smoking cessation.